Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lisdexamfetamine for Severe Obesity in Children
NCT05416125Phase 1Completed
- Sponsor
- University of Minnesota
- Start
- Dec 2023
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in childhood obesity comparing Lifestyle therapy plus placebo with Lifestyle therapy plus lisdexamfetamine (2 arms). Primary endpoint: Percent change in Body Mass Index at 24 weeks. Started Dec 2023; status: completed.
02
Drugs
lisdexamfetamine
03
Conditions
childhood obesity
Beyond the preview
Go deeper on NCT05416125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05416125.